

INTERIM FINANCIAL STATEMENTS

**DANANG PHARMACEUTICAL - MEDICAL EQUIPMENT JOINT
STOCK COMPANY**

For the period from 01/01/2025 to 30/06/2025

(reviewed)



CONTENTS

	Page
Reports of the Board of Management	02 - 03
Review report on Interim Financial Information	04 - 05
Reviewed Interim Financial Statements	06 - 42
Interim Statement of Financial Position	06 - 07
Interim Statement of Income	08
Interim Statement of Cash flows	09 - 10
Notes to the Interim Financial Statements	11 - 42

REPORT OF BOARD OF MANAGEMENT

The Board of Management of Danang Pharmaceutical - Medical Equipment Joint Stock Company ("the Company") presents its report and the Company's Interim Financial Statements for the period from 01/01/2025 to 30/06/2025.

THE COMPANY

Danang Pharmaceutical - Medical Equipment Joint Stock Company was established and operates under the Business Registration Certificate of Joint Stock Company No. 0400101404 issued by the Department of Planning and Investment of Danang City for the first time on March 22, 2005, registered for the eighteenth change on July 11, 2025.

The Company's head office is located at: No. 02, Phan Dinh Phung Street, Hai Chau Ward, Da Nang City.

BOARD OF DIRECTORS, BOARD OF MANAGEMENT AND BOARD OF SUPERVISION

Members of the Board of Directors during the period and to the reporting date are:

Mr. Do Thanh Trung	Chairman	(Appointed on 18th April 2025)
Mr. Nguyen Luong Tam	Chairman	(Resigned on 18th April 2025)
		(Appointment of board members on 18th April 2025)
Mr. Nguyen Trung	Member	
Mr. Hoang Trung Dung	Member	
Mrs. Dinh Thi Mong Van	Member	

Member of the Board of Management operated the Company during the period and as at the reporting date are:

Mr. Nguyen Luong Tam	General Director	(Appointed on 18th April 2025)
Mr. Nguyen Trung	Deputy General Director	
Mr. Nguyen Ba Hai	Deputy General Director	

Members of the Board of Supervision are:

Mrs. Nguyen Thi Yen	Head of Board of Supervision
Mrs. Pham Thi Minh Ngoc	Member
Mrs. Nguyen Thi Thanh Thuy	Member

LEGAL REPRESENTATIVE

The legal representative of the Company during the year and until the preparation of Interim Financial Statements is Mr. Nguyen Luong Tam - General Director.

Mr. Nguyen Trung - Deputy General Director in charge of operations is authorized by Mr. Nguyen Luong Tam to sign this Interim Financial Statements for the period from 01/01/2025 to 30/06/2025 pursuant to Power of Attorney No.575/UQ-CT dated 28/04/2025.

AUDITORS

The auditors of AASC Auditing Firm Company Limited have taken audit of Interim Financial Statements for the Company.

STATEMENT OF THE BOARD OF MANAGEMENT' RESPONSIBILITY IN RESPECT OF THE INTERIM FINANCIAL STATEMENTS

The Board of Management of the Company is responsible for the Interim Financial Statements which give a true and fair view of the financial position of the Company, its operating results and its cash flows for the period. In preparing those Interim Financial Statements, the Board of Management of the Company is required to:


- Establish and maintain an internal control system which is determined necessary by Board of Management and the Board of Management to ensure the preparation and presentation of Interim Financial Statements do not contain any material misstatement caused by errors or frauds;
- Select suitable accounting policies and then apply them consistently;
- Make judgments and estimates that are reasonable and prudent;
- State whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the Interim Financial Statements;
- Prepare and present the Interim Financial Statements on the basis of compliance with Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and the statutory requirements relevant to preparation and presentation of the Interim Financial Statements;
- Prepare the Interim Financial Statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The Board of Management of the Company is responsible for ensuring that accounting records are kept to reflect the financial position of the Company, with reasonable accuracy at any time and to ensure that the Interim Financial Statements comply with the current State's regulations. It is responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Board of Management of the Company confirms that Interim Financial Statements give a true and fair view of the financial position of the Company as at 30 June 2025, its operation results and cash flows for the accounting period end as at the same date in accordance with the Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and the statutory requirements relevant to the preparation and presentation of Interim Financial Statements.

Other commitments

The Board of Management pledges that the Company with Decree No. 155/2020/ND-CP dated 31 December 2020 on detailing and guiding the implementation of a number of articles of the Law on Securities and the Company does not violate the obligations of information disclosure in accordance with the regulations of the Circular No. 96/2020/TT-BTC dated 16 November 2020 issued by the Ministry of Finance guiding the disclosure of information on Securities Market and the Circular No. 68/2024/TT-BTC dated 18 September 2024 issued by Ministry of Finance amending and supplementing some articles of the Circular No. 96/2020/TT-BTC.



Nguyen Trung
Deputy General Director for Operations

Danang, 13 August 2025



No: 140825. 033 /BCTC.KT7

REVIEW REPORT ON INTERIM FINANCIAL INFORMATION

**To: Shareholders, Board of Directors and Board of Management
Danang Pharmaceutical - Medical Equipment Joint Stock Company**

We have reviewed the Interim Financial Statements of the Danang Pharmaceutical - Medical Equipment Joint Stock Company prepared on 13 August 2025 from page 06 to page 42 including: Interim Statement of Financial Position as at 30 June 2025, Interim Statement of Income, Interim Statement of Cash flows, Notes to the Interim Financial Statements for the period from 01/01/2025 to 30/06/2025.

Board of Management's Responsibility

The Board of Management of the Company is responsible for the preparation and presentation of Interim Financial Statements of the Company that give a true and fair view in accordance with Vietnamese Accounting Standards, Vietnamese Enterprise Accounting System and the statutory requirements relevant and for such internal control as management determines is necessary to enable the preparation of Interim Financial Statements interim financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express a conclusion on these Interim Financial Statements based on our review. We conducted our review in accordance with Vietnamese Standard on Review Engagements 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity.

A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Vietnamese Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Auditor's Opinion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying Interim Financial Statements does not give a true and fair view, in all material respects, of Interim Financial Statements as at 30 June 2025, and of its financial performance and its cash flows of the Danang Pharmaceutical - Medical Equipment Joint Stock Company for the six-month period then ended in accordance with the Vietnamese Accounting Standards, Vietnamese Enterprise Accounting System and the statutory requirements relevant to preparation and presentation of interim financial statements.

AASC Auditing Firm Company Limited



Cát Thi Hà

Deputy General Director

Registered Auditor

No. 0725-2023-002-1

Hanoi, 14 August 2025

INTERIM STATEMENT OF FINANCIAL POSITION

As at 30 June 2025


Code	ASSETS	Note	30/06/2025	01/01/2025
			VND	VND
100	A. CURRENT ASSETS		964,449,253,147	1,080,165,522,864
110	I. Cash and cash equivalents	03	14,470,391,226	29,127,572,681
111	1. Cash		14,470,391,226	29,127,572,681
120	II. Short-term investments	04	128,808,039,802	123,544,270,909
123	1. Held-to-maturity investments		128,808,039,802	123,544,270,909
130	III. Short-term receivables		739,719,620,651	751,533,989,814
131	1. Short-term trade receivables	05	657,596,193,294	678,163,741,281
132	2. Short-term prepayments to suppliers	06	33,417,922,844	32,531,365,975
135	3. Short-term loan receivables	07	61,100,000,000	54,100,000,000
136	4. Other short-term receivables	08	5,768,899,170	5,252,277,215
137	5. Provision for short-term doubtful debts (*)		(18,163,394,657)	(18,513,394,657)
140	IV. Inventories	10	76,608,680,285	167,152,337,595
141	1. Inventories		76,608,680,285	167,874,687,651
149	2. Provision for devaluation of inventories (*)		-	(722,350,056)
150	V. Other short-term assets		4,842,521,183	8,807,351,865
151	1. Short-term prepaid expenses	14	1,304,540,606	1,063,643,617
152	2. Deductible VAT		2,790,747,023	6,348,207,171
153	3. Taxes and other receivables from the State budget	18	747,233,554	1,395,501,077
200	B. NON-CURRENT ASSETS		91,613,822,460	92,596,742,193
220	I. Fixed assets		79,150,539,638	80,678,083,819
221	1. Tangible fixed assets	12	57,625,155,898	58,999,338,441
222	- Historical cost		84,287,359,597	83,110,038,277
223	- Accumulated depreciation		(26,662,203,699)	(24,110,699,836)
227	2. Intangible fixed assets	13	21,525,383,740	21,678,745,378
228	- Historical cost		23,760,184,541	23,760,184,541
229	- Accumulated amortization		(2,234,800,801)	(2,081,439,163)
240	II. Long-term assets in progress	11	2,507,749,968	1,939,045,712
242	1. Construction in progress		2,507,749,968	1,939,045,712
260	III. Other long-term assets		9,955,532,854	9,979,612,662
261	1. Long-term prepaid expenses	14	9,955,532,854	9,979,612,662
270	TOTAL ASSETS		1,056,063,075,607	1,172,762,265,057

INTERIM STATEMENT OF FINANCIAL POSITION

As at 30 June 2025
(Continued)


Code	CAPITAL	Note	30/06/2025 VND	01/01/2025 VND
300	C. LIABILITIES		851,034,454,734	969,000,078,856
310	I. Current Liabilities		848,343,029,734	966,518,478,856
311	1. Short-term trade payables	16	611,409,203,709	737,367,907,993
312	2. Short-term prepayments from customers	17	41,892,440,972	52,813,791,682
313	3. Taxes and other payables to the State budget	18	348,049,069	366,835,492
314	4. Payables to employees		2,337,578,624	13,072,741,850
315	5. Short-term accrued expenses	19	210,592,815	92,978,488
318	6. Short-term unearned revenue	21	869,316,206	1,125,648,396
319	7. Other short-term payables	20	1,331,115,526	1,542,870,769
320	8. Short-term borrowings and finance lease liabilities	15	189,916,157,261	160,107,128,634
322	9. Bonus and welfare fund		28,575,552	28,575,552
330	II. Non-current liabilities		2,691,425,000	2,481,600,000
337	1. Other long-term payables	20	2,691,425,000	2,481,600,000
400	D. OWNER'S EQUITY		205,028,620,873	203,762,186,201
410	I. Owner's equity	22	205,028,620,873	203,762,186,201
411	1. Contributed capital		161,163,830,000	153,493,280,000
411a	Ordinary shares with voting rights		161,163,830,000	153,493,280,000
412	2. Share Premium		9,215,548,634	9,215,548,634
414	3. Other capital		2,334,190,178	2,334,190,178
418	4. Development and investment funds		25,644,628,267	25,644,628,267
421	5. Retained earnings		6,670,423,794	13,074,539,122
421a	Retained earnings accumulated to the previous year		5,403,989,122	5,450,386,745
421b	Retained earnings of the current period		1,266,434,672	7,624,152,377
440	TOTAL CAPITAL		1,056,063,075,607	1,172,762,265,057

Preparer



Tran Khanh Linh

Chief Accountant



Tran Thi Anh Minh

Da Nang, 13 August 2025
Deputy General Director
for Operations



Nguyen Trung


INTERIM STATEMENT OF INCOME*For the period from 01/01/2025 to 30/06/2025*

Code	ITEMS	Note	The first 6 months of 2025	The first 6 months of 2024
			VND	VND
01	1. Revenue from sales of goods and rendering of services	24	502,708,707,526	648,722,225,039
02	2. Revenue deductions	25	676,561,563	1,254,517,587
10	3. Net revenue from sales of goods and rendering of services		502,032,145,963	647,467,707,452
11	4. Cost of goods sold and services rendered	26	458,319,495,265	607,222,987,846
20	5. Gross profit from sales of goods and rendering of services		43,712,650,698	40,244,719,606
21	6. Financial income	27	14,460,031,932	8,180,926,621
22	7. Financial expense	28	16,636,761,834	8,135,693,908
23	<i>In which: Interest expense</i>		3,614,800,720	1,433,764,833
25	8. Selling expense	29	36,720,140,468	27,262,169,294
26	9. General and administrative expenses	30	4,640,067,387	7,919,250,941
30	10. Net profit from operating activities		175,712,941	5,108,532,084
31	11. Other income	31	1,729,230,757	661,398,183
32	12. Other expenses		260,187,042	125,145,583
40	13. Other profit		1,469,043,715	536,252,600
50	14. Total net profit before tax		1,644,756,656	5,644,784,684
51	15. Current corporate income tax expense	32	378,321,984	1,141,160,337
60	17. Profit after corporate income tax		<u>1,266,434,672</u>	<u>4,503,624,347</u>
70	18. Basic earnings per share	33	79	279


Preparer

Chief Accountant

Da Nang, 13 August 2025

Deputy General Director
for Operations


Tran Khanh Linh



Tran Thi Anh Minh



Nguyen Trung

INTERIM STATEMENT OF CASH FLOWS

For the period from 01/01/2025 to 30/06/2025

(Indirect method)

Code	ITEMS	Note	The first 6 months of 2025 VND	The first 6 months of 2024 VND
I. CASH FLOWS FROM OPERATING ACTIVITIES				
01	1. Profit before tax		1,644,756,656	5,644,784,684
	2. Adjustment for		(290,397,299)	299,895,238
02	- Depreciation and amortization of fixed assets and investment properties		2,817,544,301	1,912,843,451
03	- Provisions		(1,072,350,056)	97,880,569
04	- Exchange gains/ losses from retranslation of monetary items denominated in foreign currency		(49,020,967)	(1,566,185)
05	- Gains/ losses from investment activities		(5,601,371,297)	(3,143,027,430)
06	- Interest expense		3,614,800,720	1,433,764,833
08	3. Operating profit before changes in working capital		1,354,359,357	5,944,679,922
09	- Increase/ decrease in receivables		30,057,760,704	(252,951,227,560)
10	- Increase/ decrease in inventories		91,266,007,366	45,786,563,611
11	- Increase/ decrease in payables (excluding interest payable/ corporate income tax payable)		(154,683,339,029)	209,898,088,938
12	- Increase/ decrease in prepaid expenses		(329,495,981)	(714,590,578)
14	- Interest paid		(3,497,186,393)	(1,574,534,693)
16	- Other receipts from operating activities		-	1,080,000
20	Net cash flow from operating activities		(35,831,893,976)	6,390,059,640
II. CASH FLOWS FROM INVESTING ACTIVITIES				
21	1. Purchase or construction of fixed assets and other long-term assets		(1,746,025,576)	(976,939,600)
23	2. Loans and purchase of debt instruments from other entities		(136,600,000,000)	(154,011,506,850)
24	3. Collection of loans and resale of debt instrument of other entities		124,336,231,107	130,960,000,000
27	4. Interest and dividend received		5,362,475,737	3,601,425,609
30	Net cash flow from investing activities		(8,647,318,732)	(20,427,020,841)
III. CASH FLOWS FROM FINANCING ACTIVITIES				
33	1. Proceeds from borrowings		497,266,140,382	371,193,405,071
34	2. Repayment of principal		(467,457,111,755)	(352,889,111,088)
40	Net cash flow from financing activities		29,809,028,627	18,304,293,983


INTERIM STATEMENT OF CASH FLOWS*For the period from 01/01/2025 to 30/06/2025**(Indirect method)*

Code	ITEMS	Note	The first 6 months of 2025	The first 6 months of 2024
			VND	VND
50	Net cash flows in the period		(14,670,184,081)	4,267,332,782
60	Cash and cash equivalents at the beginning of the period		29,127,572,681	17,184,012,943
61	Effect of exchange rate fluctuations		13,002,626	465,414
70	Cash and cash equivalents at the end of the period	03	<u>14,470,391,226</u>	<u>21,451,811,139</u>


Preparer

Chief Accountant


Da Nang, 13 August 2025

Deputy General Director
for Operations


Tran Khanh Linh



Tran Thi Anh Minh



Nguyen Trung

NOTES TO THE INTERIM FINANCIAL STATEMENTS

For the period from 01/01/2025 to 30/06/2025

1. GENERAL INFORMATION

Form of ownership

Danang Pharmaceutical - Medical Equipment Joint Stock Company was established and operates under the Business Registration Certificate of Joint Stock Company No. 0400101404 issued by the Department of Planning and Investment of Danang City for the first time on March 22, 2005, registered for the eighteenth change on July 11, 2025.

The Company's head office is located at: No. 02, Phan Dinh Phung Street, Hai Chau Ward, Da Nang City.

Charter capital of the Company is: VND 161,163,830,000.; equivalent 16,116,383. shares, par value of one share is VND 10,000.

The number of employees of the Company as at 30 June 2025 is: 209 people (as at 01 January 2025 is: 222 people).

Business field

Trading in pharmaceuticals, medicinal herbs, traditional medicine products, vaccines, medical biological products and medical equipment.

Business activities

Main business activities of the Company include:

- Business - import and export: Pharmaceuticals, medicinal materials, chemicals, medical equipment and scientific supplies, nutritional and preventive foods, vaccines and biological products, mosquito repellent incense, mosquito spray, eyeglasses, cosmetics, various types of milk, candies, vitamin-enriched beverages, mineral water, and office supplies;
- Manufacture pharmaceuticals according to the list permitted by the Ministry of Health;
- Technology transfer and medical and scientific technical services: delivery, installation, user guidance, warranty, maintenance, and repair of medical and scientific equipment;
- Rental services: offices, warehouses.

The Company's operation in the period that affects the Interim Financial Statements

In the first six months of 2025, due to a downward trend in market demand for pharmaceuticals and medical equipment, the Company's net revenue decreased by VND 145.44 billion, representing a decline of 22.46% compared to the same period in the prior year. In addition, the expansion of advertising activities for two new vaccination centers, namely Neovita Go Vap and Neovita Binh Tan, resulted in selling expenses increasing by VND 9.46 billion, equivalent to a 34.69% increase compared to the first six months of 2024. Consequently, the Company's profit before tax for the first half of 2025 decreased by VND 3.99 billion, corresponding to a reduction of 70.84% compared to the same period in 2024.

Corporate structure

The Company's member entities are	Address	Main business activities
Representative office	Hai Chau District, Da Nang City	Pharmaceutical distribution
Ha Noi branch	Thanh Xuan District, Ha Noi City	Pharmaceutical distribution
Ho Chi Minh City branch	District 10, Ho Chi Minh City	Pharmaceutical distribution

2. ACCOUNTING SYSTEM AND ACCOUNTING POLICY AT COMPANY

2.1. Accounting period and accounting currency

Annual accounting period of the Company commences from 1 January and ends as at 31 December.
The Company maintains its accounting records in Vietnam Dong (VND).

2.2. Standards and Applicable Accounting Policies

Applicable Accounting Policies

The Company applies Corporate Accounting System issued under the Circular No. 200/2014/TT-BTC dated 22 December 2014 by the Ministry of Finance and the Circular No. 53/2016/TT-BTC dated 21 March 2016 issued by Ministry of Finance amending and supplementing some articles of the Circular No. 200/2014/TT-BTC.

Declaration of compliance with Accounting Standards and Accounting System

The Company applies Vietnamese Accounting Standards and supplementary documents issued by the State. Financial Statements are prepared and presented in accordance with regulations of each standard and supplementary document as well as with current Accounting Standards and Accounting System.

2.3. Basis for the preparation of Interim Financial Statements

The Financial Statement is prepared based on historical cost principle.

The Financial Statement of the Company are prepared based on summarization of the financial statements of the independent accounting entities and the head office of the Company.

In the Financial Statement of the Company, the intra-group balances and transactions related to assets, liabilities, receivables and payables... (Note according to the actual situation of each entity: whether they have been fully eliminated or not fully eliminated).

2.4. Accounting estimates

The preparation of Interim Financial Statements in conformity with Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and legal regulations relating to financial reporting requires the Board of Management to make estimates and assumptions that affect the reported amounts of liabilities, assets and disclosures of contingent liabilities and assets at the end of the accounting period and the reported amounts of revenues and expenses during the accounting period.

The estimates and assumptions that have a material impact in the Interim Financial Statements include:

- Provision for bad debts;
- Provision for devaluation of inventory;
- Estimated allocation of prepaid expenses;
- Estimated useful life of fixed assets;
- Classification and provision of financial investments;
- Estimated income tax.

Such estimates and assumptions are continually evaluated. They are based on historical experience and other factors, including expectations of future events that may have a financial impact on Interim Financial Statements of the Company and that are assessed by the Board of Management of the Company to be reasonable under the circumstance.

2.5. Financial Instruments

Initial recognition

Financial assets

Financial assets of the Company include cash, cash equivalents, trade receivables, other receivables, lending loans, long-term and short-term investments. At initial recognition, financial assets are identified by purchasing price plus other expenses directly related to the purchase and issuance of those assets.

Financial liabilities

Financial liabilities of the Company include borrowings, trade payables, other payables and accrued expenses. At initial recognition, financial liabilities are determined by issuing price plus other expenses directly related to the issuance of those liabilities.

Subsequent measurement after initial recognition

Financial assets and financial liabilities are not revalued according to fair value at the end of the accounting period because the Circular No.210/2009/TT-BTC and prevailing statutory regulations require to present Financial statements and Notes to financial instruments but not provide any relevant instruction for assessment and recognition of fair value of financial assets and financial liabilities.

2.6. Foreign currency transactions

Foreign currency transactions during the accounting period are transferred into Vietnam Dong using the actual rate at transaction date.

Actual exchange rate when revaluing monetary items denominated in foreign currencies at the reporting date of Interim Financial Statements is determined under the following principles:

- For asset accounts, applying the bid rate of the commercial bank where the Company regularly conducts transaction;
- For cash deposited in bank, applying the bid rate of the commercial bank where the Company opens its foreign currency accounts;
- For liability accounts, applying the offer rate of the commercial bank where the Company regularly conducts transactions.

All exchange differences arising as a result of transactions or revaluation at the balance sheet date will be recorded into the financial income or expense in the accounting period.

2.7. Cash and cash equivalents

Cash comprises cash on hand, demand deposits and monetary gold held as a reserve asset, exclusive of gold classified as inventories and used as raw materials for production of goods for sale.

2.8. Financial investments

Investments held to maturity comprise term deposits (including treasury bills and promissory notes), bonds, preference shares which the issuer is required to repurchase at a certain time in the future and loans, etc. held to maturity to earn profits periodically and other held to maturity investments.

The provision for impairment of investments held to maturity is made at the end of the year based on the recoverability to establish a provision for doubtful debts in accordance with statutory regulations.

2.9. Receivables

The receivables shall be recorded in details in terms of due date, entities receivable, types of currency and other factors according to requirements for management of the Company. The receivables shall be classified into short-term receivables or long-term receivables on the Interim Financial Statements according to their remaining terms at the reporting date.

The provision for doubtful debts is made for receivables that are overdue under an economic contract, a loan agreement, a contractual commitment or a promissory note and for receivables that are not due but difficult to be recovered. Accordingly, the provisions for overdue debts shall be based on the due date stipulated in the initial sale contract, exclusive of the debt rescheduling between contracting parties and the case where the debts are not due but the debtor is in bankruptcy, in dissolution, or missing and making fleeing or estimating the possible losses or estimating the possible losses.

2.10. Inventories

Inventories are initially recognized at original cost including purchase price, processing cost and other costs incurred in bringing the inventories to their location and condition at the time of initial recognition. After initial recognition, at the reporting date, inventories are stated at the lower of cost and net realizable value.

For imported goods, the timing of inventory recognition is determined at the point when most of the risks and rewards associated with ownership of the products or goods have been transferred to the buyer in accordance with the delivery terms of Incoterms 2020.

Net realizable value is estimated based on the selling price of the inventory minus the estimated costs for completing the products and the estimated costs needed for their consumption.

The cost of inventory is calculated using weighted average method on a monthly basis for regular items that are not sold in batches and using the specific identification method for items sold in batches.

Inventory is recorded by perpetual method.

Provision for devaluation of inventories made at the end of the period is based on the excess of original cost of inventory over their net realizable value.

2.11. Fixed assets

Fixed assets (tangible and intangible) are initially stated at the historical cost. During the using time, fixed assets (tangible and intangible) are recorded at cost, accumulated depreciation and carrying amount.

Subsequent measurement after initial recognition

If these costs augment future economic benefits obtained from the use of tangible fixed assets are extended to their initial standards conditions, these costs are capitalized as an incremental in their historical cost.

Other costs incurred after tangible fixed assets have been put into operation such as repair, maintenance and overhaul costs are recognized in the Statements of Income in the accounting period in which the costs are incurred.

Fixed assets are depreciated (amortised) using the straight-line method over their estimated useful lives as follows:

- Buildings, structures	06 - 30 Years
- Other Machinery, equipment	03 - 06 years
- Vehicles, Transportation equipment	05 - 10 years
- Office equipment and furniture	03 - 10 years
- Other fixed assets	03 years
- Management software	03 - 10 years
- Land use rights	50 years
- Long-term land use rights	No depreciation

There are some of the Company's buildings and structures are used both for owner-occupied purposes and for leasing. However, the leasing activity is only implemented in the short term, and the Company plans to carry out initial production and business activities on these assets in the near future. Therefore, the value of these buildings and structures is tracked by the Company under the Tangible Fixed Assets item.

2.12. Construction in progress

Construction in progress includes fixed assets which are being purchased and constructed as at the balance sheet date and is recognised in historical cost. This includes costs of construction, installation of equipment and other direct costs.

2.13. Operating lease

Operating leases are fixed asset leasing in which a significant portion of the risks and rewards of ownership are retained by the lessor. Payments made under operating leases are charged to Statement of Income on a straight-line basis over the period of the lease.

2.14. Prepaid expenses

The expenses incurred but related to operating results of several accounting periods are recorded as prepaid expenses and are allocated to the operating results in the following accounting period.

The calculation and allocation of long-term prepaid expenses to operating expenses in each period should be based on the nature of those expenses to select a reasonable allocation method and criteria.

Types of prepaid expenses of the Company include:

- Prepaid land expenses include prepaid land rental, including those related to leased land for which the Company has received certificate of land use right but not eligible for recording as intangible fixed asset in accordance with the Circular No. 45/2013/TT-BTC dated 25 April 2013 issued by the Ministry of Finance guiding regulation on management, use and depreciation of fixed assets and other expenses related to ensure for the use of leased land. These expenses are recognized in the consolidated statement of income on a straight-line basis according to the lease term of the contract.
- Tools and supplies include assets which are possessed by the Hai Chau District, Da Nang City in an ordinary course of business, with historical cost of each asset less than 30 million dong and therefore not eligible for recording as fixed asset under current legal regulations. The historical cost of tools and supplies are allocated on the straight-line basis not exceeding 36 months.
- Other prepaid expenses are recorded at their historical costs and allocated on the straight-line basis not exceeding 36 months.

2.15. Payables

The payables shall be recorded in details in terms of due date, entities payable, types of currency and other factors according to the requirements for management of the Company. The payables shall be classified into short-term payables or long-term payables on the Interim Financial Statements according to their remaining terms at the reporting date.

2.16. Borrowings

Borrowings shall be recorded in details in terms of lending entities, loan agreement and terms of borrowings. In case of borrowings denominated in foreign currency, they shall be recorded in details in terms of types of currency.

2.17. Borrowing costs

Borrowing costs are recognized as operating expenses in the period, in which it is incurred excepting those which are directly attributable to the construction or production of a qualifying asset are capitalized as part of the cost of that asset in accordance with VAS No. 16 "Borrowing costs". Besides, regarding borrowings serving the construction of fixed assets and investment properties, the interests shall be capitalized even when the construction duration is under 12 months.

2.18. Accrued expenses

Accrued expenses include payables to goods or services received from the suppliers or provided for the customers during the reporting period, but the payments for such goods or services have not been made and other payables such as annual leave salary, expenses arising from seasonal cessation of production, interest expenses, accrued expenses to estimate the cost of goods sold estate, etc. [sửa đổi theo các loại chi phí phải trả thực tế phát sinh của đơn vị] which are recorded as operating expenses of the reporting period.

The recording of accrued expenses as operating expenses during the period shall be carried out under the matching principle between revenues and expenses during the period. Accrued expenses are settled with actual expenses incurred. The difference between accrued and actual expenses is reverted.

2.19. Unearned revenues

Unearned revenues include prepayments from customers for one or several accounting periods relating to asset leasing; interests received in advance when lending or buying debt instruments; or the difference in selling prices between deferred or instalment payment and prompt payment; revenues corresponding to the discounts offered to clients in the traditional customer loyalty, etc.

Unearned revenues are transferred to revenue from sale of goods and rendering of services with the amount corresponding to each accounting period.

2.20. Owner's equity

Owner's equity is stated at actually contributed capital of owners.

Share premium is recorded at the difference between the par value, the direct costs associated with the issuance of shares and issue price of shares (including the case of re-issuing treasury shares) and can be a positive premium (if the issue price is higher than par value and costs directly attributable to the issuance of shares) or negative premium (if the issue price is lower than par value and costs directly attributable to the issuance of shares).

Other capital is the operating capital formed from the operating results or from gifts, presents, financing, assets revaluation (if these items are allowed to be recorded as a decrease or increase in the owner's equity).

Retained earnings are used to present the Company's operating results (profit, loss) after corporate income tax and profits appropriation or loss handling of the Company.

Dividends to be paid to shareholders are recognised as a payable in Statement of Financial position after the announcement of dividend payment from the Board of Directors of the Company and announcement of cut-off date for dividend payment of Vietnam Securities Depository and Clearing Corporation.

2.21. Revenue

Revenue is recognized to extent that it is probable that the economic benefits will flow to the Company.

Revenue is measured at the fair value of the consideration received excluding discounts, sales discounts, and sales returns. The following specific recognition conditions must also be met when recognizing revenue:

Revenue from sale of goods:

- The majority of risks and benefits associated with the right to own the products or goods have been transferred to the buyer;
- The Company no longer holds the right to manage the goods as the goods owner, or the right to control the goods.

Revenue from rendering of services:

- The percentage of completion of the transaction at the Balance sheet date can be measured reliably .

Financial income

Financial incomes include income from assets yielding interest, royalties, dividends and other financial gains by the Company shall be recognised when the two conditions are satisfied:

- It is probable that the economic benefits associated with the transaction will flow to the Company;
- The amount of the revenue can be measured reliably.

2.22. Revenue deductions

Revenue deductions from sales of goods and rendering of services arising in the period include: Trade discounts, sales discounts and sales returns.

Trade discount, sales discount and sales return incurred in the same period of sale of goods and rendering of services are recorded as a decrease in revenue in the incurring period. In case goods and services are sold in the previous periods, but until the next period they are incurred as deductible items, the Company records the decrease in revenue under the following principles: If it is incurred prior to the issuance of Interim Financial Statements, it is then recorded as a decrease in revenue on the Interim Financial Statements of the reporting period (the previous period); and if it is incurred after the issuance of Interim Financial Statements, it is recorded as a decrease in revenue of incurring period (the next period).

2.23. Cost of goods sold

Cost of goods sold and services rendered are cost of finished goods, merchandises, materials sold or services rendered during the period, and recorded on the basis of matching with revenue and on a prudence basis. Cases of loss of materials and goods exceeded the norm, labour cost and fixed manufacturing overheads not allocated to the value of inventory, provision for devaluation of inventory, abnormal expenses and losses of inventories after deducting the responsibility of collective and individuals concerned, etc. is recognized fully and promptly into cost of goods sold in the year even when products and goods have not been determined as sold.

2.24. Financial expenses

Items recorded as financial expenses include:

- Borrowing costs;
- Provision for diminution in value of trading securities price; provision for losses from investment in other entities, losses from sale of foreign currency, exchange loss, etc.

The above items are recorded by the total amount arising in the period without offsetting against financial income.

2.25. Corporate income tax

a) Current corporate income tax expenses and deferred corporate income tax expenses

Current corporate income tax expenses are determined based on taxable income during the period and current corporate income tax rate.

b) Current corporate income tax rate

The Company applies the corporate income tax rate of 20% for the operating activities which has taxable income for the period from 01/01/2025 to 30/06/2025.

2.26. Earnings per share

Basic earnings per share are calculated by dividing net profit or loss after tax attributable to ordinary shareholders of the Company (after adjusting for the bonus and welfare fund and allowance for Board of Management) by the weighted average number of ordinary shares outstanding during the period.

2.27. Related Parties

The parties are regarded as related parties if that party has the ability to control or significantly influence the other party in making decisions about the financial policies and activities. The Company's related parties include:

- Companies, directly or indirectly through one or more intermediaries, having control over the Company or being under the control of the Company, or being under common control with the Company, including the Company's parent, subsidiaries and associates;
- Individuals, directly or indirectly, holding voting power of the Company that have a significant influence on the Company, key management personnel including directors and employees of the Company, the close family members of these individuals;
- Enterprises that the above-mentioned individuals directly or indirectly hold an important part of the voting power or have significant influence on these enterprises.

In considering the relationship of related parties to serve for the preparation and presentation of Interim Financial Statements, the Company should consider the nature of the relationship rather than the legal form of the relationship.

2.28. Segment information

Due to operating in the distribution of pharmaceuticals and medical equipment within the territory of Vietnam, the Company does not prepare segment reports by business segment and geographical segment.

3. CASH AND CASH EQUIVALENTS

	30/06/2025	01/01/2025
	VND	VND
Cash on hand	36,053,684	80,608,843
Demand deposits	14,326,488,558	28,595,862,787
Cash in transit	107,848,984	451,101,051
	14,470,391,226	29,127,572,681

4. FINANCIAL INVESTMENTS

a) Held to maturity investments

	30/06/2025		01/01/2025	
	Original cost	Provision	Original cost	Provision
	VND	VND	VND	VND
- Term deposits	106,908,039,802	-	62,484,270,909	-
- Others	21,900,000,000	-	61,060,000,000	-
	128,808,039,802	-	123,544,270,909	-

(1) As of June 30, 2025, term deposits with maturities of less than 12 months, amounting to VND 106,908,039,802 are held at Vietnamese commercial banks.

(2) As of 30 June 2025, the certificate of deposit issued by Vietnam Prosperity Bank SMBC Finance Company Limited had a term of 6 months, and was purchased at par value for VND 21,900,000,000.

As of June 30, 2025, some term deposits are used as collateral for the Company's loans (detailed in Note 15) with a value of VND 33,159,600,000.

5. TRADE RECEIVABLES

	30/06/2025		01/01/2025	
	Value	Provision	Value	Provision
	VND	VND	VND	VND
<i>Related parties</i>	-	-	-	-
<i>Others</i>	657,596,193,294	(18,163,394,657)	678,163,741,281	(18,513,394,657)
- Da Nang Hospital	5,734,615,309	-	3,874,516,480	-
- Hue Central Hospital	18,125,330,509	-	13,336,632,720	-
- Phuong Le Pharmaceutical and Medical Equipment Company Limited (*)	98,947,538,587	-	100,248,659,132	-
- EU Pharmaceutical Joint Stock Company (*)	-	-	18,514,541,742	-
- Cali - U.S.A Medicine Pharmacy Company Limited (*)	8,303,096,684	-	17,700,874,767	-
- S Pharmaceutical Company Limited (*)	35,711,406,048	-	10,738,461,976	-
- Hiep Thuan Thanh Medical Company Limited (*)	39,939,404,673	-	27,757,042,051	-
- Thai Nhan Pharmaceutical Cosmetics Company Limited (*)	22,020,237,082	-	70,359,953,887	-
- Gia Viet Pharmaceutical Trading Company Limited (*)	14,405,146,612	-	13,734,566,869	-
- Mr. Nguyen Hai Hung (**)	18,341,998,487	(10,911,001,197)	18,341,998,487	(10,911,001,197)
- Minh Tien Pharmaceutical Company Limited	5,785,033,068	(5,785,033,068)	6,135,033,068	(6,135,033,068)
- Other customers	390,282,386,235	(1,467,360,392)	377,421,460,102	(1,467,360,392)
	657,596,193,294	(18,163,394,657)	678,163,741,281	(18,513,394,657)

As of June 30, 2025, receivables arising from loans of Bank for Investment and Development of Vietnam – Song Han Branch and Vietnam Joint Stock Commercial Bank for Industry and Trade were pledged as collateral for loans at these banks (Details in Note 15).

(*) Some of the customer receivables are guaranteed by suppliers through a tripartite payment guarantee agreement signed between the Company, the suppliers, and the customers, and other collateral. Accordingly, the Company only has to pay the suppliers when it has collected money from the guaranteed customers. As of June 30, 2025, the balance of customer receivables guaranteed by the Company corresponds to the payable to suppliers used for guarantee with a value of VND 475,712,605,658

(**) Customer receivables are secured by a land plot in Son Tra ward, Da Nang city.

6. PREPAYMENTS TO SUPPLIERS

	30/06/2025		01/01/2025	
	Value	Provision	Value	Provision
	VND	VND	VND	VND
<i>Related parties</i>	-	-	-	-
<i>Others</i>	33,417,922,844	-	32,531,365,975	-
- Asian Dimedical Pte Ltd	1,178,847,833	-	1,178,847,833	-
- Saint Corporation	5,190,093,991	-	1,414,173,492	-
- Inbiotech L.T.D	2,390,306,489	-	8,595,194,613	-
- H&B Pharma International INC	2,622,399,049	-	6,606,048,918	-
- Medley Pharmaceuticals Ltd	3,378,050,000	-	-	-
- Other customers	18,658,225,482	-	14,737,101,119	-
	33,417,922,844	-	32,531,365,975	-

	01/01/2025		During the period		30/06/2025	
	Value	Provision	Increase	Decrease	Value	Provision
	VND	VND	VND	VND	VND	VND

- Elmich Joint Stock Company

54,100,000,000	-	61,100,000,000	54,100,000,000	61,100,000,000
54,100,000,000	-	61,100,000,000	54,100,000,000	61,100,000,000

Detail of loan receivables are as follows:

	Contract No.	Currency	Purpose of borrowing	Interest rate	Maturity date	Guarantee	30/06/2025 VND	01/01/2025 VND
Related parties Elmich Joint Stock Company	01/2025/DAP-ELM;	VND	Additional working capital	Following each disbursement contract	6 month	Unsecured	61,100,000,000	54,100,000,000
	02/2025/DAP-ELM;							
	03/2025/DAP-ELM;							
	04/2025/DAP-ELM;							
	05/2025/DAP-ELM;							
	06/2025/DAP-ELM;							
	07/2025/DAP-ELM;							
	08/2025/DAP-ELM							

61,100,000,000	54,100,000,000
----------------	----------------

8. OTHER RECEIVABLES

	30/06/2025		01/01/2025	
	Value	Provision	Value	Provision
	VND	VND	VND	VND
a.1) Details by content				
- Loan interest and deposit interest	3,474,952,446	-	3,236,056,886	-
- Mortgages	1,729,123,754	-	1,545,887,376	-
- Other receivables	564,822,970	-	470,332,953	-
	5,768,899,170	-	5,252,277,215	-
a.2) Detail by object				
Related parties	966,900,821	-	725,713,699	-
- Elmich Joint Stock Company	966,900,821	-	725,713,699	-
Others	4,801,998,349	-	4,526,563,516	-
- SMBC Vietnam Prosperity Bank Finance Company Limited	629,482,191	-	1,289,836,164	-
- Vietnam Export Import Commercial Joint Stock Bank (Eximbank)	125,624,229	-	242,906,474	-
- Saigon – Hanoi Commercial Joint Stock Bank (SHB) - Ha Noi Branch	397,589,042	-	199,452,055	-
- Vietnam Technological and Commercial Joint stock Bank (Techcombank)	139,808,219	-	-	-
- Vietnam Joint Stock Commercial Bank For Industry And Trade (Vietinbank)	6,650,960	-	42,644,384	-
- Vietnam Prosperity Joint stock Commercial Bank	1,194,772,603	-	641,493,151	-
- Joint Stock Commercial Bank for Investment and Development of Vietnam	14,124,381	-	94,010,959	-
- Others	2,293,946,724	-	2,016,220,329	-
	5,768,899,170	-	5,252,277,215	-

9. DOUBTFUL DEBTS

	30/06/2025		01/01/2025	
	Original cost	Recoverable value	Original cost	Recoverable value
	VND	VND	VND	VND
- Total value of receivables and debts that are overdue or not due but difficult to be recovered				
+ <i>Trade receivables</i>	25,672,216,918	7,508,822,261	26,022,216,918	7,508,822,261
- Quang Ngai Pharmaceutical - Medical Supplies State-owned Company Limited	917,826,085	-	917,826,085	-
- Mr. Nguyen Hai Hung	18,341,998,487	7,430,997,290	18,341,998,487	7,430,997,290
- Quang Nam Medical College	297,880,569		297,880,569	-
- Minh Tien Pharmaceutical Company	5,785,033,068		6,135,033,068	-
- Others	329,478,709	77,824,971	329,478,709	77,824,971
	25,672,216,918	7,508,822,261	26,022,216,918	7,508,822,261

10. INVENTORIES

	30/06/2025		01/01/2025	
	Original cost	Provision	Original cost	Provision
	VND	VND	VND	VND
- Goods in transit	44,611,015,017	-	125,147,795,016	-
- Raw materials	3,173,669,300	-	3,334,548,587	-
- Finished goods	2,128,376,364	-	1,992,099,654	-
- Goods	26,695,619,604	-	37,400,244,394	(722,350,056)
	76,608,680,285	-	167,874,687,651	(722,350,056)

As of June 30, 2025, the cost of inventory formed from loans from the Bank for Investment and Development of Vietnam – Song Han Branch and Vietnam Joint Stock Commercial Bank for Industry and Trade was pledged as collateral for loans at these banks (see Note 15 for details).

11. CONSTRUCTION IN PROGRESS

	30/06/2025	01/01/2025
	VND	VND
- <i>Procurement of fixed assets</i>	2,507,749,968	1,354,180,168
Storage rack system at Hoa Cam warehouse	1,236,880,168	1,236,880,168
Other acquisitions	1,270,869,800	117,300,000
- <i>Construction in progress</i>	-	584,865,544
Repair and renovation of other projects	-	584,865,544
	2,507,749,968	1,939,045,712

12. TANGIBLE FIXED ASSETS

	Buildings, structures	Machinery, equipment	Vehicles, transportation equipment	Fixed assets used in management	Other tangible fixed assets	Total
	VND	VND	VND	VND	VND	VND
Beginning balance of the period	65,633,267,262	9,010,543,628	4,573,893,014	2,677,225,887	1,215,108,486	83,110,038,277
- Purchase in the period	-	220,538,095	-	-	-	220,538,095
- Completed construction investment	956,783,225	-	-	-	-	956,783,225
Ending balance of the period	66,590,050,487	9,231,081,723	4,573,893,014	2,677,225,887	1,215,108,486	84,287,359,597
Accumulated depreciation						
Beginning balance of the period	14,959,852,821	2,705,681,511	4,295,481,896	1,286,193,127	863,490,481	24,110,699,836
- Depreciation in the period	1,871,665,122	487,772,117	43,533,642	128,325,480	20,207,502	2,551,503,863
Ending balance of the period	16,831,517,943	3,193,453,628	4,339,015,538	1,414,518,607	883,697,983	26,662,203,699
Net carrying amount						
Beginning balance of the period	50,673,414,441	6,304,862,117	278,411,118	1,391,032,760	351,618,005	58,999,338,441
Ending balance of the period	49,758,532,544	6,037,628,095	234,877,476	1,262,707,280	331,410,503	57,625,155,898

- The carrying amount of tangible fixed assets pledged as collaterals for borrowings at the end of the period: **10,791,208,701 VND**

- Cost of fully depreciated tangible fixed assets but still in use at the end of the period: **8,897,656,540 VND**

13. INTANGIBLE FIXED ASSETS

	Land use rights	Computer software	Total
	VND	VND	VND
Historical cost			
Beginning balance of the period	19,975,925,041	3,784,259,500	23,760,184,541
Ending balance of the period	<u>19,975,925,041</u>	<u>3,784,259,500</u>	<u>23,760,184,541</u>
Accumulated amortization			
- Beginning balance of the period	55,993,172	2,025,445,991	2,081,439,163
- Amortization in the period	1,617,170	151,744,468	153,361,638
Ending balance of the period	<u>57,610,342</u>	<u>2,177,190,459</u>	<u>2,234,800,801</u>
Net carrying amount			
Beginning balance	19,919,931,869	1,758,813,509	21,678,745,378
Ending balance	<u>19,918,314,699</u>	<u>1,607,069,041</u>	<u>21,525,383,740</u>

- Carrying amount of intangible fixed assets pledged as collaterals for borrowings at the end period: VND 13,521,089,694
- Cost of fully amortized intangible fixed assets but still in use at the end of period: VND 1,980,710,500

14. PREPAID EXPENSES

	30/06/2025	01/01/2025
	VND	VND
a) Short-term		
- Repair and Renovation Costs	5,003,332	1,133,331
- Rental Costs	460,727,272	164,363,636
- Insurance costs	386,636,728	81,525,910
- Others	452,173,274	816,620,740
	<u>1,304,540,606</u>	<u>1,063,643,617</u>
b) Long-term		
- Prepaid Land Lease - Hoa Cam Industrial Zone (*)	6,554,150,135	6,666,828,935
- Dispatched tools and supplies	1,744,593,343	1,012,859,945
- Insurance premiums	934,707,866	619,719,284
- Others	722,081,510	1,680,204,498
	<u>9,955,532,854</u>	<u>9,979,612,662</u>

(*) One-time prepaid land rental at Hoa Cam Industrial Park - Da Nang City for an area of 9,000 m² to serve the construction of the GSP warehouse system. As of June 30, 2025, the remaining lease term is 29 years and 2 months. The land rental cost allocated to expenses during the period is 112,678,800 VND.

15. BORROWINGS AND FINANCE LEASE LIABILITIES

	During the period				30/06/2025	
	01/01/2025		Increase		Outstanding balance	
	Outstanding balance	Amount can be paid	VND	VND	VND	Amount can be paid
	VND	VND				VND
+ Joint Stock Commercial Bank for Investment and Development of Vietnam - Song Han Branch (1)	74,772,478,104	74,772,478,104	193,168,334,446	188,107,177,804	79,833,634,746	79,833,634,746
+ Vietnam Joint Stock Commercial Bank for Industry and Trade - Da Nang Branch (2)	85,304,650,530	85,304,650,530	266,351,933,689	259,699,103,311	91,957,480,908	91,957,480,908
+ Joint Stock Commercial Bank for Foreign Trade of Vietnam - Da Nang Branch (3)	-	-	37,699,872,247	19,620,830,640	18,079,041,607	18,079,041,607
+ Personal loan (4)	30,000,000	30,000,000	46,000,000	30,000,000	46,000,000	46,000,000
	160,107,128,634	160,107,128,634	497,266,140,382	467,457,111,755	189,916,157,261	189,916,157,261

Detailed information on Short-term borrowings:

Detailed information on Short-term borrowings from banks and credit institutions is as follows:

	Contract No.	Currency	Interest rate per annum			Maturity	Loan purpose	Guarantee	30/06/2025		01/01/2025	
			Rate						VND		VND	
Others												
(1) Joint Stock Commercial Bank for Investment and Development of Vietnam - Song Han Branch	No.01/2024/7609338/HDTD	VND	Per loan	Under 6 months		Supplement working capital		1.1	171,791,115,654	160,077,128,634	74,772,478,104	

Danang Pharmaceutical - Medical Equipment Joint Stock Company
No. 02, Phan Dinh Phung Street, Hai Chau Ward, Da Nang City

Interim Financial Statements
for the period from 01/01/2025 to 30/06/2025

	Contract No.	Currency	Interest rate per annum		Maturity	Loan purpose	Guarantee	30/06/2025	01/01/2025
			Floating	Rate					
(2) Vietnam Joint Stock Commercial Bank for Industry and Trade - Da Nang Branch	No.01/2023/300029490-HĐCVHM/NHCT480-DAPHARCO	VND			Under 6 months	Supplement working capital	2.1	91,957,480,908	85,304,650,530
(3) Joint Stock Commercial Bank for Foreign Trade of Vietnam - Da Nang Branch	No.80/2025/CTD/VCB-KHDN	VND	Floating		Under 6 months	Supplement working capital	3.1	VND 18,079,041,607	VND -
(4) Personal loan		VND	Per loan		Per loan	Supplement working capital	Credit guarantee	46,000,000	30,000,000
								189,916,157,261	160,107,128,634

(1.1) Mortgage by the borrower's assets such as inventories, receivables formed from loan capital and Land Use Rights under the Asset Mortgage Contracts, including:

- + Mortgage of Land Use Rights and assets attached to land according to Real Estate Mortgage Contract No. 0007.14/HDTC dated February 28, 2014 and amended and supplemented document of Mortgage Contract No. 01/2016/7609338/SDBS dated December 30, 2016.
- + Asset Mortgage Contract No. 04/2024/7609338/HĐBĐ dated November 28, 2024;
- + Deposit Pledge Agreement No. 03/2024/7609338/HĐBĐ dated June 10, 2024;
- + Deposit Pledge Agreement No. 01/2025/7609338/HĐBĐ dated March 11, 2025;
- + Deposit Pledge Agreement No. 02/2025/7609338/HĐBĐ dated April 16, 2025;
- + Pledge of inventories and receivables arising from loan capital.

(2.1) Mortgage by the borrower's assets such as inventories, receivables formed from loan capital and Land Use Rights under the Asset Mortgage Contracts, including:

- + Asset Mortgage Contract No. QN062010/HDTC dated September 21, 2010;
- + Asset Mortgage Contract No. 07130901/HDTC dated April 8, 2008;
- + Asset Mortgage Contract No. 06130902/HDTC dated November 6, 2006;
- + Asset Mortgage Contract No. 06130901/HDTC dated November 6, 2006;
- + Deposit Pledge Agreement No. 01/2024/HĐBĐ/NHCT480-DARPHACO dated April, 2025;
- + Pledge of inventories and receivables arising from loan capital.

(3.1) Mortgage by the borrower's assets such as inventories, receivables formed from loan capital under the Mortgage Contracts, including:

- + Deposit Pledge Agreement No. 50/2025/V/CB-ĐN dated March 17, 2025;
- + Pledge of inventories and receivables arising from loan capital.

Loans from banks and other credit institutions have been secured by mortgage contracts with lenders and have been fully registered for secured transactions.

16. TRADE PAYABLES

	30/06/2025		01/01/2025	
	Outstanding balance	Amount can be paid	Outstanding balance	Amount can be paid
	VND	VND	VND	VND
<i>Related parties</i>	-	-	27,843,750	27,843,750
- Megram Joint Stock Company	-	-	27,843,750	27,843,750
<i>Others</i>	611,409,203,709	611,409,203,709	737,340,064,243	737,340,064,243
- Inbiotech L.T.D (*)	8,217,115,548	8,217,115,548	33,969,559,659	33,969,559,659
- Axon Drugs Private Ltd	14,403,829,026	14,403,829,026	18,109,218,894	18,109,218,894
- Delta Pharma Limited (*)	27,242,744,384	27,242,744,384	42,868,880,451	42,868,880,451
- Growena Impex Company (*)	-	-	31,916,233,301	31,916,233,301
- Incepta Pharmaceuticals Ltd	59,217,593,330	59,217,593,330	78,833,726,748	78,833,726,748
- Pharmix Corporation	6,562,932,715	6,562,932,715	6,382,093,009	6,382,093,009
- Novapri Lifescience Private Limited	33,932,142,374	33,932,142,374	13,414,150,515	13,414,150,515
- Rv Group (S) Pte. Ltd	34,227,650,574	34,227,650,574	25,698,625,503	25,698,625,503
- Square Pharmaceutical Ltd	62,271,495,133	62,271,495,133	40,226,727,870	40,226,727,870
- Other suppliers	365,333,700,625	365,333,700,625	445,920,848,293	445,920,848,293
	611,409,203,709	611,409,203,709	737,367,907,993	737,367,907,993

(*) Some payables to suppliers are guaranteed for customer receivables through a tripartite payment guarantee agreement signed between the Company, the supplier, and the customer. Accordingly, the Company is only required to make payments to the suppliers after collecting funds from the guaranteed customers. See Note 5 for more details.

17. PREPAYMENTS FROM CUSTOMERS

	30/06/2025	01/01/2025
	VND	VND
<i>Related parties</i>	-	-
<i>Others</i>	41,892,440,972	52,813,791,682
- Thien An Pharmaceutical Company Limited	2,463,811,021	7,764,215,946
- Da Phuc Pharmaceutical Company Limited	-	9,676,122,972
- Lien Mai Pharmaceutical Company Limited	5,450,924,050	5,450,924,050
- Huy Cuong Pharmaceutical Company Limited	6,974,846,333	-
- Other suppliers	27,002,859,568	29,922,528,714
	41,892,440,972	52,813,791,682

18. TAX AND OTHER PAYABLES TO THE STATE BUDGET

	Opening receivable VND	Opening payables VND	Payables in the period VND	Actual payment in the period VND	Closing receivables VND	Closing payables VND
- Value-added tax	270,410,963	14,810,304	94,722,662,603	94,458,060,141	-	9,001,803
- Export, import duties	-	-	3,478,702,763	3,479,168,187	465,424	-
- Corporate income tax	1,125,090,114	-	378,321,984	-	746,768,130	-
- Personal income tax	-	352,025,188	3,113,234,992	3,126,212,914	-	339,047,266
- Land tax and land rental	-	-	537,114,756	537,114,756	-	-
- Fees, charges and other payables	-	-	20,000,000	20,000,000	-	-
	1,395,501,077	366,835,492	102,250,037,098	101,620,555,998	747,233,554	348,049,069

The Company's tax settlements are subject to examination by the tax authorities. Because the application of tax laws and regulations on many types of transactions is susceptible to varying interpretations, amounts reported in the Interim Financial Statements could be changed at a later date upon final determination by the tax authorities.

19. ACCRUED EXPENSES

	30/06/2025	01/01/2025
	VND	VND
- Interest expense	210,592,815	92,978,488
	210,592,815	92,978,488

20. OTHER PAYABLES

	30/06/2025	01/01/2025
	VND	VND
a) Short-term payables		
a.1) Details by content	1,331,115,526	1,542,870,769
- Surplus of assets awaiting resolution	428,469,853	70,478,826
- Trade union fee	77,985,874	76,721,942
- Social insurance	28,632,446	28,369,284
- Short-term deposits, collateral received	424,000,000	415,000,000
- Other payables	372,027,353	952,300,717
	1,331,115,526	1,542,870,769
a.2) Details by object	1,331,115,526	1,542,870,769
- Social insurance at Da Nang City	28,632,446	28,369,284
- Other objects	1,302,483,080	1,514,501,485
	1,331,115,526	1,542,870,769
b) Long-term payables		
b.1) Details by content	2,691,425,000	2,481,600,000
- Long-term deposits, collateral received	2,691,425,000	2,481,600,000
	2,691,425,000	2,481,600,000
b.2) Details by object	2,691,425,000	2,481,600,000
- GIMGAMED Pharmaceutical Company Limited	1,500,000,000	1,500,000,000
- Buymed Logistics Company Limited	787,725,000	787,725,000
- Other objects	403,700,000	193,875,000
	2,691,425,000	2,481,600,000

21. UNEARNED REVENUES

	30/06/2025	01/01/2025
	VND	VND
- Deferred revenue from land lease (*)	869,316,206	1,125,648,396
	869,316,206	1,125,648,396

(*) Revenue received in advance from leasing premises in Cam Le ward, Da Nang city and in Hai Chau ward, Da Nang city.

22. OWNER'S EQUITY

a) Changes in owner's equity

	Contributed capital	Share premium	Other capital	Development and investment funds	Retained earnings	Total
	VND	VND	VND	VND	VND	VND
Beginning balance of the previous period	153,493,280,000	9,215,548,634	2,334,190,178	25,644,628,267	5,450,386,745	196,138,033,824
Profit for previous period	-	-	-	-	4,503,624,347	4,503,624,347
Ending balance of previous period	<u>153,493,280,000</u>	<u>9,215,548,634</u>	<u>2,334,190,178</u>	<u>25,644,628,267</u>	<u>9,954,011,092</u>	<u>200,641,658,171</u>
Beginning balance of the current period	153,493,280,000	9,215,548,634	2,334,190,178	25,644,628,267	13,074,539,122	203,762,186,201
Increase in capital in current period	7,670,550,000	-	-	-	(7,670,550,000)	-
Profit for current period	-	-	-	-	1,266,434,672	1,266,434,672
Ending balance of the current period	<u>161,163,830,000</u>	<u>9,215,548,634</u>	<u>2,334,190,178</u>	<u>25,644,628,267</u>	<u>6,670,423,794</u>	<u>205,028,620,873</u>

Following to Resolution No. 10/2025/NQ-ĐHĐCĐ dated 18 April 2025 of the Annual General Meeting of Shareholders, the Company announced the distribution of 2024 profits as follows:

- Total number of shares expected to be issued: 767,466 shares;
- Total par value of expected issuance: VND 7,674,660,000;
- Issuance target: Existing shareholders whose names appear in the list of shareholders on the record date for entitlement to stock dividends;
- Exercise ratio: 100:5 (on the record date, a shareholder holding 100 shares will receive 5 additional shares as stock dividends, equivalent to a 5% stock dividend ratio);
- Rounding principle and treatment of fractional shares: The number of shares issued to each shareholder as stock dividends will be rounded down to the nearest whole number; any fractional shares (if any) will be cancelled and not issued;
- Source of funds: From undistributed profit after tax as at 31 December 2024, based on the audited financial statements for 2024.
- The Company completed the issuance of shares for the purpose of paying stock dividends on 13 June 2025, in accordance with the Share Issuance Result Report No. 850/BC-CT disclosed on 23 June 2025, and completed the registration of amendments to the Enterprise Registration Certificate on 11 July 2025.
- On 14 July 2025, the Company received confirmation of the adjustment to the registered number of shares – stock code DDN – from the Vietnam Securities Depository and Clearing Corporation. On 24 July 2025, the Company was approved by the Hanoi Stock Exchange to amend its trading registration for the shares of Danang Pharmaceutical – Medical Equipment Joint Stock Company.

b) Details of Contributed capital

	Ending the period	Rate	Beginning the period	Rate
	VND	%	VND	%
Megram Joint Stock Company	82,204,690,000	51.01	78,290,190,000	51.01
Danapha Pharmaceutical Joint Stock Company	11,547,800,000	7.17	10,997,910,000	7.17
Mr. Pham Van Truong	10,710,000,000	6.55	10,050,000,000	6.55
Others	56,701,340,000	35.27	54,155,180,000	35.27
	161,163,830,000	100.00	153,493,280,000	100.00

c) Capital transactions with owners and distribution of dividends and profits

	The first 6 months of 2025	The first 6 months of 2024
	VND	VND
Owner's contributed capital		
- At the beginning of the period	153,493,280,000	153,493,280,000
- Increase in the period	7,670,550,000	-
- At the end of the period	161,163,830,000	153,493,280,000

d) Share

	30/06/2025	01/01/2025
Quantity of Authorized issuing shares	16,116,383	15,349,328
Quantity of issued shares	16,116,383	15,349,328
- Common shares	16,116,383	15,349,328
Quantity of outstanding shares in circulation	16,116,383	15,349,328
- Common shares	16,116,383	15,349,328
Par value per share (VND):	10,000	10,000

e) the Company's reserves

	30/06/2025	01/01/2025
	VND	VND
- Development and investment funds	25,644,628,267	25,644,628,267
	<u>25,644,628,267</u>	<u>25,644,628,267</u>

23. OFF STATEMENT OF FINANCIAL POSITION ITEMS AND OPERATING LEASE COMMITMENT

a) Operating asset for leasing

The Company is currently leasing a property located at 06 Tran Quoc Toan Street, Hai Chau Ward, Da Nang City, with an area of 400.6 m2 under an operating lease agreement until September 9, 2027.

The Company has signed a warehouse lease agreement at Hoa Cam Industrial Park - Da Nang City with a total area of 2,127.6 m2 under an operating lease agreement until June 1, 2026.

b) Operating leased assets

The Company has signed land lease contracts in Da Nang City for the purposes of building offices, product stores and warehouses. Under these contracts, the company is required to pay annual land rental fees until the contract expiration date, in accordance with the prevailing regulations of the State.

The Company signed a land lease contract at Hoa Cam Industrial Park - Da Nang City with an area of 9,000 m2 to serve the construction of a drug storage warehouse and a medical supplies factory. The company paid the land rent once for the lease period from January 2019 to August 2054.

The Company entered into Land Use Right and Existing Property Lease Contract No. 01-2024/HDDTQSDDD dated 10 October 2024 for land lot No. 1272, map sheet No. 77, cadastral records of Binh Tan Ward, Ho Chi Minh City, for the purpose of operating vaccination services and providing medical services in line with its business activities. The lease term is from 15 November 2024 to 14 November 2029.

The Company entered into a lease agreement for premises located at No. 115B, Street No. 10 (new address: 305 Nguyen Van Khoi Street), Thong Tay Hoi Ward, Ho Chi Minh City, for the purpose of operating vaccination services and providing medical services in line with its business activities. The lease term is 5 years, commencing on 8 August 2024 and ending on 7 August 2029.

c) Assets held under trust

The company is accepting the mortgage of certain customers' assets to secure accounts receivable, including: Inventory stored at the Hanoi and Ho Chi Minh City branches of some customers; A land lot in Man Thai Ward, Son Tra District, Da Nang City.

d) Foreign currencies

	Unit	30/06/2025	01/01/2025
- US Dollars (\$)	USD	18,627.67	18,640.87
- Euro (€)	EUR	309.49	309.32

24. TOTAL REVENUE FROM SALES OF GOODS AND RENDERING OF SERVICES

	The first 6 months of 2025	The first 6 months of 2024
	VND	VND
Revenue from pharmaceutical sales	457,731,893,695	611,509,511,734
Revenue from medical equipment sales	7,390,823,163	2,629,178,981
Revenue from services provided	37,585,990,668	34,583,534,324
	502,708,707,526	648,722,225,039

25. REVENUE DEDUCTIONS

	The first 6 months of 2025	The first 6 months of 2024
	VND	VND
- Trade discounts	538,447,481	943,752,553
- Sale discounts	12,602,654	-
- Sale returns	125,511,428	310,765,034
	676,561,563	1,254,517,587

26. COST OF GOODS SOLD

	The first 6 months of 2025	The first 6 months of 2024
	VND	VND
Cost of pharmaceutical sales	442,001,307,298	595,077,418,495
Cost of medical equipment sales	5,959,102,195	1,951,791,592
Cost of services rendered	11,081,435,828	10,193,777,759
Provision for devaluation of inventories	(722,350,056)	-
	458,319,495,265	607,222,987,846

27. FINANCIAL INCOME

	The first 6 months of 2025	The first 6 months of 2024
	VND	VND
Interest income	5,601,371,297	3,143,027,430
Gain on exchange difference in the period	8,475,056,476	4,576,023,339
Gain on exchange difference at the period-end	49,020,967	1,566,185
Interest from deferred payment sale or payment discount	334,583,192	460,309,667
	14,460,031,932	8,180,926,621
In which: Financial income received from related parties (Detailed in Note 39)	1,708,602,191	29,589,041

28. FINACIAL EXPENSES

	The first 6 months of 2025	The first 6 months of 2024
	VND	VND
Interest expenses	3,614,800,720	1,433,764,833
Loss on exchange difference in the period	12,986,892,286	6,642,717,171
Other financial expenses	35,068,828	59,211,904
	16,636,761,834	8,135,693,908

29. SELLING EXPENSES

	The first 6 months of 2025	The first 6 months of 2024
	VND	VND
Labour expenses	17,082,953,542	16,301,007,018
Depreciation expenses	2,486,349,101	1,206,354,470
Expenses of outsourcing services	6,635,991,650	1,730,519,518
Other expenses in cash	10,514,846,175	8,024,288,288
	36,720,140,468	27,262,169,294

30. GENERAL AND ADMINISTRATIVE EXPENSE

	The first 6 months of 2025	The first 6 months of 2024
	VND	VND
Labour expenses	2,755,587,640	4,267,233,012
Depreciation expenses	27,989,964	425,300,442
Provision expenses/ Reversal of provision expenses	(350,000,000)	97,880,569
Expenses of outsourcing services	459,712,545	715,468,171
Other expenses in cash	1,746,777,238	2,413,368,747
	4,640,067,387	7,919,250,941

In which: General and administrative expenses purchased from related parties

(Detailed in Note 39)

3,937,066	6,015,424
------------------	------------------

31. OTHER INCOME

	The first 6 months of 2025	The first 6 months of 2024
	VND	VND
Collected fines	7,500,000	1,002,240
Income from unpayable commission	1,561,949,879	471,819,969
Others	159,780,878	188,575,974
	1,729,230,757	661,398,183

32. CURRENT CORPORATE INCOME TAX EXPENSES

	The first 6 months of 2025	The first 6 months of 2024
	VND	VND
<i>Corporate income tax from main business activities</i>		
Total profit before tax	1,644,756,656	5,644,784,684
Increase	246,853,262	61,017,000
- <i>Ineligible expenses</i>	246,853,262	61,017,000
Taxable income	1,891,609,918	5,705,801,684
Current corporate income tax expense (tax rate 20%)	378,321,984	1,141,160,337
Tax payable at the beginning of the period	(1,125,090,114)	(1,307,870,073)
Tax paid in the period	-	-
Corporate income tax payable at the end of the period	(746,768,130)	(166,709,736)

33. BASIC EARNINGS PER SHARE

Basic earnings per share distributed to common shareholders of the Company are calculated as follows:

	The first 6 months of 2025	The first 6 months of 2024 (Adjusted)
	VND	VND
Net profit after tax	1,266,434,672	4,503,624,347
Profit distributed to common shares	1,266,434,672	4,503,624,347
Average number of outstanding common shares in circulation in the period	16,116,383	16,116,383
Basic earnings per share	79	279

The Company has not planned to make any distribution to Bonus and welfare fund, bonus for the Board of Management from the net profit after tax at the date of preparing Interim Financial Statements.

Basic earnings per share have been adjusted retrospectively as regulated by the Vietnamese Accounting Standards No. 30 – Basic earnings per share.

As at 30 June 2025, the Company does not have shares with dilutive potential for earnings per share.

34. BUSINESS AND PRODUCTIONS COST BY ITEMS

	The first 6 months of 2025	The first 6 months of 2024
	VND	VND
Raw materials	4,157,903,110	4,210,582,933
Labour expenses	21,041,463,489	21,512,006,889
Depreciation expenses	2,704,865,501	1,800,164,651
Provision/Reversal expenses	(350,000,000)	97,880,569
Expenses of outsourcing services	7,369,084,503	11,543,722,827
Other expenses in cash	12,493,899,761	997,558,068
	47,417,216,364	40,161,915,937

35. FINANCIAL INSTRUMENTS**Financial risk management**

Financial risks that the Company may face risks including: market risk, credit risk and liquidity risk.

The Company has developed its control system to ensure the reasonable balance between cost of incurred risks and cost of risk management. Board of Management of the Company is responsible for monitoring the risk management process to ensure the appropriate balance between risk and risk control.

Market risk

The Company may face with the market risk such as: changes in prices, exchange rates and interest rates.

Exchange rate risk:

The Company bears the risk of interest rates due to the transaction made in a foreign currency other than VND such as: borrowings and debts, revenue, cost, importing materials, good, machinery and equipment....

Interest rate risk:

The Company bears the risk of interest rates due to the fluctuation in fair value of future cash flow of a financial instrument in line with changes in market interest rates if the Company has time or demand deposits, borrowings and debts subject to floating interest rates. The Company manages interest rate risk by analyzing the market competition situation to obtain interest beneficial for its operation purpose.

Credit Risk

Credit risk is the risk of financial loss to the Company if a counterparty fails to perform its contractual obligations. The Company has credit risk from operating activities (mainly to trade receivables) and financial activities (including deposits, loans and other financial instruments), detailed as follows:

	Under 1 year	From 1 to 5 years	Over 5 years	Total
	VND	VND	VND	VND
As at 30/06/2025				
Cash and cash equivalents	14,434,337,542	-	-	14,434,337,542
Trade and other receivables	645,201,697,807	-	-	645,201,697,807
Loans	189,908,039,802	-	-	189,908,039,802
	849,544,075,151	-	-	849,544,075,151
As at 01/01/2025				
Cash and cash equivalents	29,046,963,838	-	-	29,046,963,838
Trade and other receivables	664,902,623,839	-	-	664,902,623,839
Loans	177,644,270,909	-	-	177,644,270,909
	871,593,858,586	-	-	871,593,858,586

Liquidity Risk:

Liquidity risk is the risk that the Company has trouble in settlement of its financial obligations due to the lack of funds. Liquidity risk of the Company is mainly arises from different maturity of its financial assets and liabilities.

Due date for payment of financial liabilities based on expected payment under the contracts (based on cash flow of the original debts) as follows:

	Under 1 year	From 1 to 5 years	Over 5 years	Total
	VND	VND	VND	VND
As at 30/06/2025				
Borrowings and debts	189,916,157,261	-	-	189,916,157,261
Trade and other payables	612,740,319,235	2,691,425,000	-	615,431,744,235
Accrued expenses	210,592,815	-	-	210,592,815
	802,867,069,311	2,691,425,000	-	805,558,494,311
As at 01/01/2025				
Borrowings and debts	160,107,128,634	-	-	160,107,128,634
Trade and other payables	738,910,778,762	2,481,600,000	-	741,392,378,762
Accrued expenses	92,978,488	-	-	92,978,488
	899,110,885,884	2,481,600,000	-	901,592,485,884

The Company believes that risk level of loan repayment is controllable. The Company has the ability to pay due debts from cash flows from its operating activities and cash received from mature financial assets.

36. ADDITIONAL INFORMATION FOR THE ITEMS IN STATEMENT OF CASH FLOWS

	The first 6 months of 2025	The first 6 months of 2024
	VND	VND
a) Proceeds from borrowings during the period		
Proceeds from ordinary contracts;	497,266,140,382	371,193,405,071
b) Actual repayments on principal during the period		
Repayment on principal from ordinary contracts;	467,457,111,755	352,889,111,088

37. OTHER INFORMATIONS

Accounts receivable are guaranteed for payment by suppliers

As of June 30, 2025 and January 1, 2025, the Company's receivables from import-entrusted customers are guaranteed for payment by suppliers through Guarantee Agreements signed between three parties with the main terms including:

- Parties signing the agreement: Supplier, Danang Pharmaceutical and Medical Equipment Joint Stock Company and Customer;
- Guarantee period: Signed separately for each contract, effective until the Customer pays all receivables to the Company;
- Main content: The Company is not responsible for paying the supplier if the customer has not paid the Company. At the same time, if the customer is late in paying beyond the deadline (specified in each Guarantee Agreement), the Company is allowed to offset the customer's outstanding payment obligation with the debt payable to the supplier.

Details of the balance of receivables from customers guaranteed under the Guarantee Agreements as at 31 December 2024 are presented in Note 5.

38. SUBSEQUENT EVENTS AFTER THE REPORTING PERIOD

There have been no significant events occurring after the reporting period, which would require adjustments or disclosures to be made in the Interim Financial Statements.

39. TRANSACTION AND BALANCES WITH RELATED PARTIES

List and relation between related parties and the Company are as follows:

Related parties	Relationship
Megram Joint Stock Company	Parent company
Danapha Pharmaceutical Joint Stock Company	Major
Elimich Joint Stock Company	Same group
The members of the Board of Directors, the Board of Management, the Board of Supervision	

In addition to the information with related parties presented in the above Notes, during the period the Company has transactions with related parties as follows:

	The first 6 months of 2025	The first 6 months of 2024
	VND	VND
Financial revenue	1,708,602,191	29,589,041
Elmich Joint Stock Company	1,708,602,191	29,589,041
General and administrative expenses	3,937,066	6,015,424
Megram Joint Stock Company	3,937,066	6,015,424
Loan	61,100,000,000	18,000,000,000
Elmich Joint Stock Company	61,100,000,000	18,000,000,000
Loan recovery	54,100,000,000	9,000,000,000
Elmich Joint Stock Company	54,100,000,000	9,000,000,000

Transactions with the other related parties as follows:

	Position	The first 6 months of 2025	The first 6 months of 2024
		VND	VND
Remuneration of key management persons			
Remuneration of the Board of Directors			
- Do Thanh Trung	Chairman	106,000,000	-
	(Appointed on 18 April 2025)	-	-
- Nguyen Luong Tam	Member, General Director	1,597,465,952	107,200,000
	(Appointed on 18 April 2025)	-	-
- Nguyen Trung	Member, Deputy of General director	594,160,063	335,321,218
- Hoang Trung Dung	Member of Independent Board of Directors	106,000,000	50,000,000
- Dinh Thi Mong Van	Member	76,000,000	-
		2,479,626,015	492,521,218
Salary (Salary and Remuneration) of Supervisory Board			
- Nguyen Thi Yen	Head of Supervisory Board	26,000,000	-
- Pham Thi Minh Ngoc	Member	21,000,000	-
- Nguyen Thi Thanh Thuy	Member	157,961,308	107,964,449
		204,961,308	107,964,449

Salary, reward and the other benefits of the Director and the other managers


	Position	The first 6 months of 2025	The first 6 months of 2024
		VND	VND
- Nguyen Ba Hai	Deputy of General director	843,457,200	-

In addition to the above related parties' transactions, other related parties did not have any transactions during the period and have no balance at the end of the accounting period with the Company.

40. COMPARATIVE FIGURES

The comparative figures in Interim Statement of Financial Position, Interim Statement of Income, Interim Statement of Cash flows and corresponding notes are taken in Interim Financial Statements for year ended as at 31 December 2024 audited by AASC Auditing Firm Company Limited. The comparative figures in the Interim Statement of Income, Interim Statement of Cash flows and corresponding notes are those of the interim financial statements reviewed for the accounting period from 1 January 2024 to 30 June 2024.

Preparer



Tran Khanh Linh

Chief Accountant



Tran Thi Anh Minh

Da Nang, 13 August 2025

**Deputy General Director
for Operations**



Nguyen Trung